Parecoxib - Getting to the heart of the matter [3]

Anaesthesia

Volumn 62, Issue 3, 2007, Pages 291-292

  Schug, S A ^a   Joshi, G P ^b   Camu, F ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; VALDECOXIB; ISOXAZOLE DERIVATIVE;

ANALGESIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG CONTRAINDICATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; LETTER; PERIOPERATIVE PERIOD; POSTOPERATIVE PAIN; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOSIS; CHEMICALLY INDUCED DISORDER; EVIDENCE BASED MEDICINE; NOTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; ISOXAZOLES;

EID: 34047130151     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2007.05005_1.x     Document Type: Letter

References (10)

1. Maxwell M, Nathanson M. Parecoxib - getting to the heart of the matter. Anaesthesia 2006; 61: 823-5.
2. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: A population-based case-control study. Archives of Internal Medicine 2005; 165: 978-84.
3. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81.
4. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. British Medical Journal 2006; 332: 1302-8.
5. FDA. http://www.fda.gov/cder/drug/infopage/cox2/COX2qa.htm accessed 10 November 2006.
6. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery 2003; 125: 1481-92.
7. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New England Journal of Medicine 2005; 352: 1081-91.
8. FDA. http://www.fda.gov/cder/drug/infopage/COX2/NSAIDmedguide.pdf accessed 10 November 2006.
9. Schug SA, Camu F, Joshi GP. Cardiovascular safety of the cyclooxygenase-2 selective inhbitor parecoxib sodium: Review of pooled data from surgical studies. European Journal of Anaesthesiology 2006; 23 (Suppl. 37): A-849.
10. Schug SA. The role of COX-2 inhibitors in the treatment of postoperative pain. Journal of Cardiovascular Pharmacology 2006; 47 (Suppl. 1): S82-6.